推荐产品
一般描述
吡非尼酮(5-甲基-1-苯基-2-[1H]-吡啶酮)是合成的吡啶 衍生物。
应用
吡非尼酮用于:
- 作为兔的术后滴眼剂,分析其抗纤维化作用,改进青光眼滤过手术
- 作为抗瘢痕形成剂,检查其是否影响兔植入青光眼引流装置(GDD)后的异物反应
- 在人眼眶成纤维细胞(hOF)原代培养物中测试其抗纤维化潜力
- 作为肿瘤坏死因子(TNFα)抑制剂,研究其在缺氧中的作用
生化/生理作用
吡非尼酮可抑制胶原生成和成纤维细胞增殖。在多种肺纤维化动物模型和临床试验中显示出抗纤维化和抗炎属性。
吡非尼酮用于治疗特发性肺纤维化(IPF)。有助于减少肺功能下降引起的衰弱,延长无进展生存期。吡非尼酮可抑制人Tenon′s 囊成纤维细胞胶原蛋白的增殖和收缩。
警示用语:
Warning
危险声明
危险分类
Acute Tox. 4 Oral
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
个人防护装备
dust mask type N95 (US), Eyeshields, Gloves
Transplantation, 94(2), 114-122 (2012-06-30)
Pirfenidone (PFD) is an antifibrotic agent with beneficial effects on proinflammatory disorders. In this study, we further investigated PFD and long-acting form, "deuterated PFD," immune-modulating properties by evaluating their effects on mouse dendritic cells (DCs). The effects of PFD on
Suppression of TGF-beta pathway by pirfenidone decreases extracellular matrix deposition in ocular fibroblasts in vitro
Testing, 12(2), e0172592-e0172592 (2017)
Drugs, 71(13), 1721-1732 (2011-09-10)
Pirfenidone is an orally administered pyridine that has orphan designation for the treatment of mild to moderate idiopathic pulmonary fibrosis (IPF) in the EU. Pirfenidone 2403 mg/day for 72 weeks administered to patients with IPF was associated with a significantly lower
Therapeutic advances in respiratory disease, 6(2), 107-114 (2012-02-16)
Pirfenidone is the first antifibrotic agent to be approved for the treatment of pulmonary fibrosis. Idiopathic pulmonary fibrosis (IPF) is one of the idiopathic interstitial pneumonias with the worst prognoses; approximately half of patients die within 3-5 years, and the
Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis
European Respiratory Review, 26(146), 170057-170057 (2017)
商品
Bioactive small molecules for immune system signaling target identification/validation and antibiotics, antivirals, and antifungals offered.
我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门